Neuro-oncology
Journal
Overview
publication venue for
-
Sustained imaging response and hearing preservation with low-dose bevacizumab in sporadic vestibular schwannoma.
2019
-
EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil.
2007
-
Atypical teratoid/rhabdoid tumor evolving from an optic pathway ganglioglioma: case study.
2006
-
Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma.
2023
-
A Nationwide Evaluation of Bevacizumab-based Treatments in Paediatric Low-Grade Glioma in the UK: Safety. Efficacy, Visual Morbidity and Outcomes.
2022
-
Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients..
24.
2022
-
Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study..
24.
2022
-
Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children's Oncology Group study..
24.
2022
-
EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults..
24.
2022
-
EEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations..
24.
2022
-
SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors..
23.
2021
-
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)..
23.
2021
-
A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study..
23.
2021
-
Clinical trial of proton craniospinal irradiation for leptomeningeal metastases..
23.
2021
-
Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment..
22.
2020
-
A combined approach of convection-enhanced delivery of peptide nanofiber reservoir to prolong local DM1 retention for diffuse intrinsic pontine glioma treatment..
22.
2020
-
Long-term clinically relevant rodent model of methotrexate-induced cognitive impairment..
22.
2020
-
MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors..
21.
2019
-
Genetic variants and cognitive functions in patients with brain tumors..
21.
2019
-
A low percentage of metastases in deep brain and temporal lobe structures..
21.
2019
-
Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool..
20.
2018
-
Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma..
20.
2018
-
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma..
20.
2018
-
In vivo evaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature..
20.
2018
-
The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades..
20.
2018
-
Early posttreatment assessment of MRI perfusion biomarkers can predict long-term response of lung cancer brain metastases to stereotactic radiosurgery..
20.
2018
-
Long-term exposure to ambient air pollution and incidence of brain tumor: the European Study of Cohorts for Air Pollution Effects (ESCAPE)..
20.
2018
-
Prognostic awareness, prognostic communication, and cognitive function in patients with malignant glioma..
19.
2017
-
Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma..
19.
2017
-
Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors..
19.
2017
-
Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors..
19.
2017
-
Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma..
19.
2017
-
The radiosurgery fractionation quandary: single fraction or hypofractionation?.
19.
2017
-
COMT, BDNF, and DTNBP1 polymorphisms and cognitive functions in patients with brain tumors..
18.
2016
-
Cox-2-derived PGE2 induces Id1-dependent radiation resistance and self-renewal in experimental glioblastoma..
18.
2016
-
Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study..
18.
2016
-
Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study..
18.
2016
-
Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma..
18.
2016
-
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma..
18.
2015
-
A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation..
18.
2015
-
Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade..
18.
2015
-
Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients..
18.
2015
-
Nevospheres from neurocutaneous melanocytosis cells show reduced viability when treated with specific inhibitors of NRAS signaling pathway..
18.
2015
-
Rates and risks for late referral to hospice in patients with primary malignant brain tumors..
18.
2015
-
Imaging patterns predict patient survival and molecular subtype in glioblastoma via machine learning techniques..
18.
2015
-
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma..
17.
2015
-
Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)..
17.
2015
-
Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma..
17.
2015
-
Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD)..
16 Suppl 7.
2014
-
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma..
17.
2014
-
Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study..
17.
2014
-
Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors..
16.
2014
-
Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma..
16.
2014
-
Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas..
16.
2014
-
Transcriptional diversity of long-term glioblastoma survivors..
16.
2014
-
The potential of theragnostic ¹²⁴I-8H9 convection-enhanced delivery in diffuse intrinsic pontine glioma..
16.
2014
-
Phase II trial of patupilone in patients with brain metastases from breast cancer..
16.
2014
-
MDA-9/syntenin is a key regulator of glioma pathogenesis..
16.
2013
-
Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas..
16.
2013
-
Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas..
16.
2013
-
Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target..
15.
2013
-
Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery..
15.
2013
-
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma..
15.
2012
-
MicroRNA profiling in pediatric pilocytic astrocytoma reveals biologically relevant targets, including PBX3, NFIB, and METAP2..
15.
2012
-
A phase I/II trial of vandetanib for patients with recurrent malignant glioma..
14.
2012
-
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02..
14.
2012
-
A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker..
14.
2012
-
Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center..
14.
2012
-
Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas..
14.
2012
-
Initial treatment patterns over time for anaplastic oligodendroglial tumors..
14.
2012
-
Challenging the current paradigm of melanoma progression: brain metastasis as isolated first visceral site..
14.
2012
-
Cognitive functions in primary CNS lymphoma after single or combined modality regimens..
14.
2011
-
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer..
13.
2011
-
A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma..
13.
2011
-
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas..
13.
2011
-
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?.
13.
2011
-
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors..
13.
2011
-
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03..
13.
2011
-
Late relapse in primary central nervous system lymphoma: clonal persistence..
13.
2011
-
Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group..
13.
2011
-
Bevacizumab in recurrent high-grade pediatric gliomas..
12.
2010
-
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)..
12.
2010
-
ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma..
12.
2010
-
A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas..
12.
2010
-
High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma..
12.
2010
-
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas..
12.
2009
-
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy..
12.
2009
-
DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma..
12.
2009
-
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)..
11.
2009
-
Occupational exposure to magnetic fields and the risk of brain tumors..
11.
2009
-
Oxidative response gene polymorphisms and risk of adult brain tumors..
10.
2008
-
Genetic variation in insulin-like growth factors and brain tumor risk..
10.
2008
-
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas..
10.
2008
-
Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features..
10.
2008
-
The utility of body FDG PET in staging primary central nervous system lymphoma..
10.
2008
-
Survey of treatment recommendations for anaplastic oligodendroglioma..
9.
2007
-
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study..
8.
2006
-
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up..
8.
2006
-
Variation in genes relevant to aromatic hydrocarbon metabolism and the risk of adult brain tumors..
8.
2006
-
Meningioma and schwannoma risk in adults in relation to family history of cancer..
6.
2004
-
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study..
6.
2004
-
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study..
6.
2004
-
A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma..
5.
2003
-
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas..
3.
2001
-
The new kid on the block: suicide gene therapy to modulate cancer immunosurveillance for children with high-risk malignant brain tumors.
2019
-
The trials of neuro-oncology clinical research.
2018
-
Reappraising the 2016 WHO classification for diffuse glioma.
2017
-
FGFR-TACC approaches the first turn in the race for targetable GBM mutations.
2017
-
"Comment on Hatzoglou et al.: Dynamic contrast-enhanced MRI perfusion vs 18FDG PET/CT in differentiating brain tumor progression from radiation injury"-Reply.
2017
-
Pediatric spinal cord gliomas-low grade but high risk for recurrence: should we treat them differently from intracranial low-grade gliomas?.
23.
2021
-
IDH glioma radiogenomics in the era of deep learning..
23.
2021
-
The promise of molecular profiling of choroid plexus tumors for diagnostic and prognostic stratification: where to go from here?.
18.
2016
-
PI3K pathway inhibition in GBM—is there a signal?.
17.
2015
-
Timing (and biology) are everything..
16.
2014
-
Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma.
2019
-
MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.
2019
-
Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.
2018
-
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.
2017
-
Pediatric high-grade glioma: biologically and clinically in need of new thinking.
2017
-
Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.
2016
-
MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis.
2016
-
Is there a role for early chemotherapy in the management of pituitary adenomas?
2016
-
Toward precision medicine in glioblastoma: the promise and the challenges.
2015
-
Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges.
2014
-
Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.
2014
-
Whither whole brain radiotherapy for primary CNS lymphoma?
2014
-
Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.
2014
-
Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium.
2008
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)